AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.8 |
Market Cap | 36.45M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.61 |
PE Ratio (ttm) | -4.49 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3 |
Volume | 740,997 |
Avg. Volume (20D) | 1,817,800 |
Open | 3.00 |
Previous Close | 2.51 |
Day's Range | 2.60 - 3.11 |
52-Week Range | 0.25 - 4.49 |
Beta | undefined |
About NXL
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various m...
Analyst Forecast
According to 1 analyst ratings, the average rating for NXL stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 9.49% from the latest price.
Next Earnings Release
Analysts project revenue of $30.00K, reflecting a 46.08% YoY growth and earnings per share of -0.12, making a 20.00% increase YoY.
9 months ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...